- Home
- KRUS vs ABEO Comparison
KRUS vs ABEO Comparison
Compare KRUS & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRUS | ABEO |
|---|---|---|
| Founded | 2008 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.4M | 399.5M |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | KRUS | ABEO |
|---|---|---|
| Price | $40.32 | $4.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $67.00 | $18.88 |
| AVG Volume (30 Days) | 250.0K | ★ 1.4M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.75 | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $282,763,000.00 | $2,998,000.00 |
| Revenue This Year | $16.97 | $804.33 |
| Revenue Next Year | $18.28 | $119.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.88 | ★ 258.18 |
| 52 Week Low | $33.97 | $4.00 |
| 52 Week High | $80.84 | $7.65 |
Technical Indicators
Market Signals| Indicator | KRUS | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 32.36 |
| Support Level | $33.97 | $4.23 |
| Resistance Level | $41.99 | $5.36 |
| Average True Range (ATR) | 1.75 | 0.19 |
| MACD | 0.54 | -0.01 |
| Stochastic Oscillator | 72.53 | 1.49 |
Price Performance
Historical ComparisonAbout KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.